Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.95 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded ACAD stock?
Rallies tracks politician and congressional stock disclosures for ACAD, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Rallies tracks politician and congressional stock disclosures for ACAD, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in ACAD?
Yes. Rallies tracks politician and congressional stock disclosures for ACAD, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ACAD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.
